Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.

View in: PubMed

subject areas

Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Double-Blind Method
Double-Blind Method
Female
Female
Gene Expression Regulation
Gene Expression Regulation
Humans
Humans
Immunosuppressive Agents
Immunosuppressive Agents
Injections, Intravenous
Injections, Intravenous
Interferon Type I
Interferon Type I
Interferon-alpha
Interferon-alpha
Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
Male
Male
Middle Aged
Middle Aged
RNA, Messenger
RNA, Messenger
Severity of Illness Index
Severity of Illness Index
Treatment Outcome
Treatment Outcome
Young Adult
Young Adult

authors with profiles

Joan Merrill